JPMorgan Downgrades Cerevel Therapeutics (CERE) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. CSCO
2. SPY
3. CBRS
4. COHR
5. BTGO
6. NVDA
7. WDAY
8. WYFI
9. AMAT
10. STUB

March 17, 2023 5:49 AM EDT
Get Alerts CERE Hot Sheet
Price: $44.96 --0%

Rating Summary:
    5 Buy, 13 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 9 | New: 7
Join SI Premium – FREE

JPMorgan analyst Jessica Fye downgraded Cerevel Therapeutics (NASDAQ: CERE) from Overweight to Neutral with a price target of $29.00 (from $40.00).


For an analyst ratings summary and ratings history on Cerevel Therapeutics click here. For more ratings news on Cerevel Therapeutics click here.


Shares of Cerevel Therapeutics closed at $24.32 yesterday.


You May Also Be Interested In





Related Categories

Analyst PT Change, Downgrades